Amid Giddiness Over First-Ever Gene-Silencing Drug’s Approval Is An Acknowledgment Of Its Limitations

Right now, the RNAi drug is limited to cells that go through the liver, which is -- in relative terms -- easy to target. Getting the drug to other tissue, like the skin or brain, is more challenging. “It’s always been the same problem. And it’s delivery, delivery, delivery,” Steven Dowdy, a cancer biologist at the University of California, San Diego’s school of medicine, tells Stat. “It’s always been the 800-pound gorilla in the room.”

from Kaiser Health News https://ift.tt/2vIPcNo